COVID-19: A review of the proposed pharmacological treatments
The emerging pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge for healthcare systems globally.
The clinical course of COVID-19 and its ability to rapidly create widespread infection has major implications, warranting vigorous infection prevention and control measures. As the confirmed number of cases has surpassed 5.6 million worldwide and continues to grow, the potential severity of the disease and its deadly complications requires urgent development of novel therapeutic agents to both prevent and treat COVID-19.
Although vaccines and specific drug therapies have yet to be discovered, ongoing research and clinical trials are being conducted to investigate the efficacy of repurposed drugs for treating COVID-19. In this review, the authors discuss drug candidates that have been suggested to treat COVID-19. These include anti-viral agents, immunomodulatory agents, and adjunctive agents, among other miscellaneous agents. The mechanisms of action and further pharmacological properties were also explored, with a particular focus on the evidence-based safety and efficacy of each agent.
I sat down with Dr. Aviv Ouanounou, the corresponding author of the article, and asked him to tell us about the review and its findings. There are two additional authors of the review Sarah Lam and Andrew Lombardi, from the Faculty of Dentistry at the University of Toronto.
We hope you find the conversation useful. We welcome your thoughts, questions and/or suggestions about this post and other topics. Leave a comment in the box below or send us your feedback by email.
Until next time!
Chiraz Guessaier, CDA Oasis Manager